Project Grant R01CA294770
Award Date 8/15/25
Completion Date 7/31/30
Dollars Obligated $670K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
- This federal Project Grant award of $472,921.00, awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research to investigate the role of the CR1 signaling pathway in regulating cellular plasticity and breast cancer progression. The University of Utah is conducting this research, which aims to understand the molecular mechanisms by which CR1 mediates stress-adaptive cell state changes in breast cancer cells and their surrounding microenvironment. The project...
- This federal Project Grant award of $154,000.00 was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to the University of Utah. The project, titled "One Cell, One Cancer: A Novel Genetic Approach to Mouse Models of Human Cancer Initiation," aims to develop a novel dual-recombinase system, termed "Flp-out," to induce oncogenic mutations in single cells for improved modeling of pancreatic ductal adenocarcinoma (PDAC) initiation...
- This $483,395 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by The Institute For Cancer Research (ICR) to investigate targeting the P300/CBP proteins as a novel therapeutic approach for renal cell carcinoma (RCC). The key objectives are to examine the therapeutic potential of inhibiting P300/CBP in clear cell RCC, and establish the association between P300/CBP expression and disease progression, drug-resistance, and...
- This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The $267,298 award, effective from February 1, 2025 to January 31, 2027, will support in vitro and in vivo studies to test the sensitivity of TRCC cells to CDK4/6 inhibition,...
- This Project Grant award of $423,500.00 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research at the University of Utah to uncover fundamental cell signaling mechanisms that can be therapeutically targeted in disease. The award, with a performance period from July 1, 2025 to June 30, 2030, focuses on two key projects: Addressing the regulation and function of kinases in the "dark...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $230,711 project grant to The Trustees of Columbia University in the City of New York, Health Sciences Division, to conduct research on overcoming resistance to hedgehog inhibitor treatments in basal cell carcinomas. The 2-year project aims to elucidate the role of the BRD9 chromatin remodeling complex in promoting an immunosuppressive tumor microenvironment that drives resistance to hedgehog-targeted therapies....
- The National Cancer Institute, a component of the National Institutes of Health, awarded a $249,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Vanderbilt University. The grant, spanning January 1, 2025 to December 31, 2027, will fund research to understand the kinetics of receptor tyrosine kinase (RTK) signaling and biased agonism in cancer. Specifically, the project will employ advanced single-molecule fluorescence microscopy techniques in living cells to...
- The federal Project Grant award for $172,193 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) located in Massachusetts. The goal of this 5-year project is to characterize subtype-specific gene regulatory elements in translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer, by identifying differentially active transcription factors, determining their metabolic...
- The federal Project Grant award for "TARGETING P2X7 RECEPTOR IN RENAL CELL CARCINOMA", totaling $1,269,000.00, was awarded to The Institute For Cancer Research, a non-profit subsidiary of Temple University, by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports biomedical research focused on developing new treatments for kidney cancer, a key health concern for military service members and veterans. The Institute For...